Evidence map›Paper›PMID 33416118›Full record

Trial reportInternational journal of molecular medicine2021

MicroRNA‑34a‑5p expression in the plasma and in its extracellular vesicle fractions in subjects with Parkinson's disease: An exploratory study.

Ilaria Grossi, Annalisa Radeghieri, Lucia Paolini, Vanessa Porrini, Andrea Pilotto, Alessandro Padovani, Alessandra Marengoni, Alessandro Barbon, Arianna Bellucci, Marina Pizzi and 2 more

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. The Role of miRNAs in Parkinson's Disease: A Systematic Review.International journal of molecular sciences · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Exosomal microRNAs in Parkinson's disease: insights into biomarker potential and disease pathology.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Review
  11. Evolving Role of Exosomes in Plastic and Reconstructive Surgery and Dermatology.Plastic and reconstructive surgery. Global open · 2024
    Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Ilaria Grossi *Department of Molecular and Translational Medicine, University of Brescia, I‑25123 Brescia, Italy.
Annalisa Radeghieri *Department of Molecular and Translational Medicine, University of Brescia, I‑25123 Brescia, Italy.
Lucia PaoliniDepartment of Molecular and Translational Medicine, University of Brescia, I‑25123 Brescia, Italy.
Vanessa PorriniDepartment of Molecular and Translational Medicine, University of Brescia, I‑25123 Brescia, Italy.
Andrea PilottoNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, I‑25123 Brescia, Italy.
Alessandro PadovaniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, I‑25123 Brescia, Italy.
Alessandra MarengoniGeneral Medicine and Geriatrics Unit, Department of Clinical and Experimental Sciences, University of Brescia, I‑25123 Brescia, Italy.
Alessandro BarbonDepartment of Molecular and Translational Medicine, University of Brescia, I‑25123 Brescia, Italy.
Arianna BellucciDepartment of Molecular and Translational Medicine, University of Brescia, I‑25123 Brescia, Italy.
Marina PizziDepartment of Molecular and Translational Medicine, University of Brescia, I‑25123 Brescia, Italy.
Alessandro SalviDepartment of Molecular and Translational Medicine, University of Brescia, I‑25123 Brescia, Italy.
Giuseppina De PetroDepartment of Molecular and Translational Medicine, University of Brescia, I‑25123 Brescia, Italy.
University of Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is an important disabling age‑related disorder and is the second most common neurodegenerative disease. Currently, no established molecular biomarkers exist for the early diagnosis of PD. Circulating microRNAs (miRNAs), either vesicle‑free or encapsulated in extracellular vesicles (EVs), have emerged as potential blood‑based biomarkers also for neurodegenerative diseases. In this exploratory study, we focused on miR‑34a‑5p because of its well‑documented involvement in neurobiology. To explore a differential profile of circulating miR‑34a‑5p in PD, PD patients and age‑matched control subjects were enrolled. Serial ultracentrifugation steps and density gradient were used to separate EV subpopulations from plasma according to their different sedimentation properties (Large, Medium, Small EVs). Characterization of EV types was performed using western blotting and atomic force microscopy (AFM); purity from protein contaminants was checked with the colorimetric nanoplasmonic assay. Circulating miR‑34a‑5p levels were evaluated using qPCR in plasma and in each EV type. miR‑34a‑5p was significantly up‑regulated in small EVs devoid of exogenous protein contaminants (pure SEVs) from PD patients and ROC analysis indicated a good diagnostic performance in discriminating patients from controls (AUC=0.74, P<0.05). Moreover, miR‑34a‑5p levels in pure SEVs were associated with disease duration, Hoehn and Yahr and Beck Depression Inventory scores. These results underline the necessity to examine the miRNA content of each EV subpopulation to identify miRNA candidates with potential diagnostic value and lay the basis for future studies to validate the overexpression of circulating miR‑34a‑5p in PD via the use of pure SEVs.

Indexed as

Gene Expression RegulationAgedAged, 80 and overCirculating MicroRNAExtracellular VesiclesFemaleHumansMaleMicroRNAsParkinson DiseaseCirculating MicroRNAMicroRNAsMIRN34 microRNA, humanextracellular vesicleshuman plasmamicroRNAsmiR-34a-5pParkinson's disease

Identifiers

PMID33416118
PMCPMC7797475
OpenAlexW3107216683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.